Logo image of ALNY

ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Overview

USA - NASDAQ:ALNY - US02043Q1076 - Common Stock

456.35 USD
-4.64 (-1.01%)
Last: 10/3/2025, 8:22:07 PM
456.35 USD
0 (0%)
After Hours: 10/3/2025, 8:22:07 PM

ALNY Key Statistics, Chart & Performance

Key Statistics
52 Week High484.21
52 Week Low205.87
Market Cap59.82B
Shares131.08M
Float125.76M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.47
PEN/A
Fwd PE86.03
Earnings (Next)10-23 2025-10-23/bmo
IPO05-28 2004-05-28
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ALNY short term performance overview.The bars show the price performance of ALNY in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80

ALNY long term performance overview.The bars show the price performance of ALNY in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200

The current stock price of ALNY is 456.35 USD. In the past month the price increased by 0.96%. In the past year, price increased by 70.29%.

ALNYLAM PHARMACEUTICALS INC / ALNY Daily stock chart

ALNY Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 22.09 413.22B
AMGN AMGEN INC 13.66 160.37B
GILD GILEAD SCIENCES INC 14.56 139.83B
VRTX VERTEX PHARMACEUTICALS INC 23.81 103.40B
REGN REGENERON PHARMACEUTICALS 13.15 63.59B
ARGX ARGENX SE - ADR 86.3 48.96B
ONC BEONE MEDICINES LTD-ADR 5.55 37.77B
INSM INSMED INC N/A 33.22B
BNTX BIONTECH SE-ADR N/A 25.36B
BIIB BIOGEN INC 9.99 23.44B
NTRA NATERA INC N/A 22.97B
GMAB GENMAB A/S -SP ADR 16.21 20.66B

About ALNY

Company Profile

ALNY logo image Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.

Company Info

ALNYLAM PHARMACEUTICALS INC

675 W Kendall St

Cambridge MASSACHUSETTS 02142 US

CEO: John M. Maraganore

Employees: 2230

ALNY Company Website

ALNY Investor Relations

Phone: 16175518200

ALNYLAM PHARMACEUTICALS INC / ALNY FAQ

What is the stock price of ALNYLAM PHARMACEUTICALS INC today?

The current stock price of ALNY is 456.35 USD. The price decreased by -1.01% in the last trading session.


What is the ticker symbol for ALNYLAM PHARMACEUTICALS INC stock?

The exchange symbol of ALNYLAM PHARMACEUTICALS INC is ALNY and it is listed on the Nasdaq exchange.


On which exchange is ALNY stock listed?

ALNY stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ALNYLAM PHARMACEUTICALS INC stock?

36 analysts have analysed ALNY and the average price target is 458.7 USD. This implies a price increase of 0.51% is expected in the next year compared to the current price of 456.35. Check the ALNYLAM PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ALNYLAM PHARMACEUTICALS INC worth?

ALNYLAM PHARMACEUTICALS INC (ALNY) has a market capitalization of 59.82B USD. This makes ALNY a Large Cap stock.


How many employees does ALNYLAM PHARMACEUTICALS INC have?

ALNYLAM PHARMACEUTICALS INC (ALNY) currently has 2230 employees.


What are the support and resistance levels for ALNYLAM PHARMACEUTICALS INC (ALNY) stock?

ALNYLAM PHARMACEUTICALS INC (ALNY) has a support level at 446.39 and a resistance level at 458.5. Check the full technical report for a detailed analysis of ALNY support and resistance levels.


Is ALNYLAM PHARMACEUTICALS INC (ALNY) expected to grow?

The Revenue of ALNYLAM PHARMACEUTICALS INC (ALNY) is expected to grow by 57.26% in the next year. Check the estimates tab for more information on the ALNY EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ALNYLAM PHARMACEUTICALS INC (ALNY) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ALNYLAM PHARMACEUTICALS INC (ALNY) stock pay dividends?

ALNY does not pay a dividend.


When does ALNYLAM PHARMACEUTICALS INC (ALNY) report earnings?

ALNYLAM PHARMACEUTICALS INC (ALNY) will report earnings on 2025-10-23, before the market open.


What is the Price/Earnings (PE) ratio of ALNYLAM PHARMACEUTICALS INC (ALNY)?

ALNYLAM PHARMACEUTICALS INC (ALNY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.47).


What is the Short Interest ratio of ALNYLAM PHARMACEUTICALS INC (ALNY) stock?

The outstanding short interest for ALNYLAM PHARMACEUTICALS INC (ALNY) is 2.96% of its float. Check the ownership tab for more information on the ALNY short interest.


ALNY Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to ALNY. When comparing the yearly performance of all stocks, ALNY is one of the better performing stocks in the market, outperforming 91.53% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ALNY Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ALNY. The financial health of ALNY is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALNY Financial Highlights

Over the last trailing twelve months ALNY reported a non-GAAP Earnings per Share(EPS) of -2.47. The EPS decreased by -311.67% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -6.99%
ROE -127.33%
Debt/Equity 4.1
Chartmill High Growth Momentum
EPS Q2Q%-292.31%
Sales Q2Q%17.26%
EPS 1Y (TTM)-311.67%
Revenue 1Y (TTM)5.02%

ALNY Forecast & Estimates

36 analysts have analysed ALNY and the average price target is 458.7 USD. This implies a price increase of 0.51% is expected in the next year compared to the current price of 456.35.

For the next year, analysts expect an EPS growth of 153.61% and a revenue growth 57.26% for ALNY


Analysts
Analysts80
Price Target458.7 (0.51%)
EPS Next Y153.61%
Revenue Next Year57.26%

ALNY Ownership

Ownership
Inst Owners98.86%
Ins Owners0.2%
Short Float %2.96%
Short Ratio3.11